Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Maravai LifeSciences Holdings, Inc. - Class A common stock
(NQ:
MRVI
)
3.080
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Maravai LifeSciences Holdings, Inc. - Class A common stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics
↗
May 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Horizon Therapeutics Stock Flashes Improved Technical Strength; Nears Buy Point
↗
May 18, 2021
Horizon Therapeutics stock had its Relative Strength Rating upgraded to 75 -- a welcome improvement, but still shy of the 80 or better score you look for.
Via
Investor's Business Daily
Biotech Zai Lab Stock Sees Relative Strength Rating Jump To 83
↗
May 14, 2021
A Relative Strength Rating upgrade for ZaiLabLimited shows improving technical performance.
Via
Investor's Business Daily
Stock Market Rally Struggles With Inflation Spike; Tesla Sales Fall, Elon Musk Turns On Bitcoin As Coinbase Reports
↗
May 14, 2021
The market rally tested key levels as inflation fears mounted. Tesla's China sales dived as CEO Elon Musk dissed Bitcoin.
Via
Investor's Business Daily
Earnings Scheduled For May 10, 2021
↗
May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report...
Via
Benzinga
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2021 Earnings Call Transcript
↗
May 11, 2021
MRVI earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
IPO Stock Maravai Lifesciences Crushes First-Quarter Forecasts
↗
May 10, 2021
Late Monday, Maravai reported adjusted income of 26 cents per share on $148.21 million in sales. But the fresh IPO stock was unmoved in after-hours trading.
Via
Investor's Business Daily
Topics
Initial Public Offering
Coronavirus Vaccine Plays Moderna, Maravai, West Pharmaceutical Among 5 Stocks Near Buy Points
↗
April 17, 2021
Coronavirus vaccine maker Moderna and vaccine suppliers Maravai and West Pharmaceutical are among five stocks near buy points.
Via
Investor's Business Daily
Topics
Supply Chain
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today